NEW YORK (TheStreet) -- Becton, Dickinson and Co. (BDX) shares are up 1.24% to $129 in early market trading on Tuesday after the company released its fourth quarter earnings results before the opening bell today.
The medical supply product manufacturer reported earnings of $1.68 per diluted share on an adjusted basis, 14 cents per share better than it reported during the same period last year and 4 cents better than analysts were expecting this year.
The company generated a 4% increase in revenue, reporting $2.20 billion for the quarter, ahead of analysts $2.16 billion estimates as the company's bottom line was helped by better than expected sales in its diabetes care and drug-delivery segments.
TheStreet Ratings team rates BECTON DICKINSON & CO as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate BECTON DICKINSON & CO (BDX) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: BDX Ratings Report